ClinicalTrials.gg
RecruitingNCT07250269Updated Nov 6, 2026

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

A Phase 1 interventional study of GC012F Injection in Relapsed/Refractory AL Amyloidosis, sponsored by Gracell Biotechnologies (Shanghai) Co., Ltd.. Recruiting at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Gracell Biotechnologies (Shanghai) Co., Ltd. (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 6, 2026Site recruiting status changedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 29 studies in Immunoglobulin Light-chain Amyloidosis with a site in China — 19 open to participants now, 21 under way, 2 of them phase 3. Immunoglobulin Light-chain Amyloidosis · China.

Planned enrollment
21st of 24
12 · median 36
Started
2025
with 7 others
Phase 1
4 of 29
2 open now
Primary completion
2028-11
later than 19 of 20 live
Registered
24th of 29
by date
Lead sponsor
1 of 29
Gracell Biotechnologies (Shanghai) Co., Ltd.

Among the 29 studies in Immunoglobulin Light-chain Amyloidosis with a site in China, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 8 that started in 2025, is one of 4 in phase 1, reaches primary completion later than 19 of the 20 other live ones, and was the 24th registered.

Immunoglobulin Light-chain Amyloidosis

239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.

Browse Immunoglobulin Light-chain Amyloidosis studies →

Open to participants now

19 of the 29 studies in Immunoglobulin Light-chain Amyloidosis with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Immunoglobulin Light-chain Amyloidosis with a site in China, or all of them as a file.
02

Study summary

This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.

Read the detailed description

This is a Phase 1b, open-label, multicenter, non-randomized study to evaluate the safety, tolerability, and efficacy of GC012F in adult participants with relapsed/refractory AL amyloidosis. A single-arm design was chosen for the study due to the absence of approved therapies for use as a concurrent control for this patient population. In the study, the safety of different doses of GC012F will be evaluated and the RP2D will be selected based on the totality of clinical safety, preliminary efficacy, CK and PD data.

03

Conditions studied

  • Relapsed/Refractory AL Amyloidosis

Keywords

  • AZD0120
  • GC012F
  • Amyloidosis
  • AL Amyloidosis
  • CAR-T
  • Cell Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed histopathological diagnosis of AL amyloidosis
  2. One or more organs currently or historically impacted by AL amyloidosis according to consensus guidelines
  3. Measurable hematologic disease: dFLC > 20 mg/L or serum M-protein > 5g/L
  4. disease or refractory disease defined as a need for additional therapy after at least 1 line of anti-plasma cell-directed therapy.
  5. performance status of 0 to 1
  6. Must be able and willing to adhere to the study visit schedule and other protocol requirements
  7. Women of (WCBP) must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Have any other form of amyloidosis other than AL amyloidosis
  2. Mayo Stage IIIb AL amyloidosis
  3. Oxygen saturation \< 95% on room air
  4. Systolic blood pressure \<100mmHg
  5. Cardiac exclusion criteria:

    1. Mayo Stage IIIb AL amyloidosis as defined by

      - NT-proBNP>8500ng/L, and

      • high sensitivity cardiac troponin T ≥ 50 ng/L cardiac Troponin T ≥ 0.035 ng/mL or cardiac Troponin I ≥ 0.1 ng/mL
    2. NT-proBNP levels as follows:

      - NT-proBNP ≥ 2000 ng/L (for dose escalation portion)

      • NT-proBNP \< 2000 and > 8500 ng/L (for dose extension portion)
    3. class III or IV

5. Extensive GI involvement with evidence of active GI bleeding/risk of bleeding as determined by Investigator 6. Prior therapies:

  1. CAR T cell therapy directed at any target
  2. Prior BCMA-targeting therapy
  3. Prior treatment with any approved or T cell engaging therapies (including T cell-directed bispecific or trispecific therapies) at any target within the last 6 months.

7. Toxicity from previous anti-cancer or anti-PC-directed therapy did not resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.

8. Active plasma cell leukemia at the time of screening 9. Multiple myeloma defined as clonal bone marrow PCs ≥10% and any one or more of the following myeloma defining events (deemed as attributable to multiple myeloma by Investigator) 10. Seropositive for 11. Serologic status reflecting active or C:

  1. Positive HBsAg, or
  2. Patients with positive core antibody (anti-HBc) and HBV-DNA positive.
  3. Patients with positive antibody and HCV RNA positive.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    GC012F

    GC012F Injection

    Drug: GC012F Injection

Interventions

  • The investigational agent, GC012F, is an autologous BCMA/CD19 dual directed CAR product under investigation for the treatment of patients with RRMM, ELMM, SLE, and B NHL.

    Also known as: AZD0120

06

What researchers measure

Primary outcomes

  1. Number of Participants With incidence and severity of Treatment-emergent Adverse Events

    Time frame: Through study completion, an average of 2 years

  2. Number of participants with dose-limiting toxicities during dose escalation phase

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. Levels of GC012F in blood over time in participants with AL amyloidosis

    Time frame: Through study completion, an average of 2 years

  2. Percentage of participants who achieve a hematologic response based on modified response criteria (CR, VGPR, or low dFLC PR)

    Time frame: Through study completion, an average of 2 years

  3. Percentage of participants who achieve a complete response based on hematologic response criteria for AL amyloidosis

    Time frame: Through study completion, an average of 2 years

07

Study locations

9 of 9 sites recruiting
  • Research Site
    Beijing, 100034, China
    Recruiting
  • Research Site
    Beijing, 100070, China
    Recruiting
  • Research Site
    Beijing, CN-100730, China
    Recruiting
  • Research Site
    Changchun, 130021, China
    Recruiting
  • Research Site
    Guangzhou, 510100, China
    Recruiting
  • Research Site
    Hangzhou, 310003, China
    Recruiting
  • Research Site
    Suzhou, 215006, China
    Recruiting
  • Research Site
    Wenzhou, 325000, China
    Recruiting
  • Research Site
    Wuhan, 430022, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Nov 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2025
First posted
Nov 26, 2025
StartActual
Oct 29, 2025
Primary completionEst.
Nov 24, 2028
CompletionEst.
Nov 24, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Research Site · Hangzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Wuhan, ChinaNot yet recruiting→Recruiting
Nov 6, 2026
Enrollment
9→12
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Research Site · Hangzhou, ChinaNot yet recruiting→Recruiting
    • Research Site · Wuhan, ChinaNot yet recruiting→Recruiting
    Enrollment 9→12
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07250269
Collaborators
Suzhou Gracell Biotechnologies Co., Ltd.
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Oct 29, 2025
Primary completion
Nov 24, 2028 (estimated)
Completion
Nov 24, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

Start the discussion